Trial Profile
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary) ; Carboplatin; Cisplatin; Doxorubicin liposomal; Etoposide; Gemcitabine; Irinotecan; Paclitaxel; Pemetrexed; Taxanes; Vinorelbine
- Indications Carcinoma; Fallopian tube cancer; Gastrointestinal cancer; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms QUADRUPLE THREAT; TRIPLE THREAT
- Sponsors EpicentRx
- 18 Feb 2023 Results (n=90 with small cell cancer , high-grade neuroendocrine carcinoma, non-small cell lung cancer and genitourinary cancer ) assessing Effect of RRx-001 on nephrotoxicity of cisplatin/etoposide in patients with solid tumors presented at the 2023 Genitourinary Cancers Symposium
- 15 Feb 2023 According to an EpicentRx media release, data from this trial will be presented as a poster at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO).
- 06 Oct 2022 According to an EpicentRx media release, Primary endpoint (Overall Survival) has been met.